ArticleFrontiers in medicine2026
Plasma PZP level elevation: a potential correlate of diabetic kidney disease progression.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage renal disease in type 2 diabetes mellitus (T2DM) patients. Recent studies have demonstrated that pregnancy zone protein (PZP), a hepatic cytokine, plays a role in regulating glucose and lipid metabolism. This retrospective study aimed to investigate the connection between plasma PZP concentrations and DKD. Materials and methods: All participants were stratified by estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). The discovery cohort included 130 participants, from whom plasma samples were collected for four-dimensional data-independent acquisition (4D-DIA) quantitative proteomics. In contrast, plasma PZP concentrations were measured using the enzyme-linked immunosorbent assay (ELISA) in a validation cohort of 283 participants. Comparisons of clinical parameters, Spearman's rho correlation analysis, logistic regression, and receiver operating characteristic (ROC) curve analysis were performed. Data were retrieved from public databases, and plasma PZP expression was simultaneously assessed in db/db mice and in primary hepatocytes treated with high glucose and palmitic acid (HGPA). Results: 4D-DIA quantitative proteomics identified PZP as a differentially expressed protein in DKD patients. In the validation cohort, plasma PZP levels were significantly increased in DKD patients. Spearman's rho correlation analysis revealed positive correlations between plasma PZP concentrations and systolic blood pressure (SBP), HbA1c, low-density lipoprotein (LDL), Cr, blood urea nitrogen (BUN), and UACR, as well as negative correlations with high-density lipoprotein (HDL) and eGFR. A multiple logistic regression analysis demonstrated a significant correlation between PZP and DKD progression (mild DKD: OR = 1.007; severe DKD: OR = 1.011). The ROC curve area was 0.8143. Plasma PZP levels in db/db mice were notably elevated, and a positive correlation with the UACR was observed. Moreover, PZP mRNA expression in HGPA-treated primary hepatocytes was twice as high as that in untreated cells. Conclusion: In summary, elevated plasma PZP levels are independently associated with DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.